OA12720A - Methods for treating ocular neovascular diseases. - Google Patents

Methods for treating ocular neovascular diseases. Download PDF

Info

Publication number
OA12720A
OA12720A OA1200400130A OA1200400130A OA12720A OA 12720 A OA12720 A OA 12720A OA 1200400130 A OA1200400130 A OA 1200400130A OA 1200400130 A OA1200400130 A OA 1200400130A OA 12720 A OA12720 A OA 12720A
Authority
OA
OAPI
Prior art keywords
vegf
eye
nucleic acid
therapy
patients
Prior art date
Application number
OA1200400130A
Other languages
English (en)
Inventor
David R Guyer
Original Assignee
Eyetech Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyetech Pharmaceuticals filed Critical Eyetech Pharmaceuticals
Publication of OA12720A publication Critical patent/OA12720A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200400130A 2001-11-09 2002-11-08 Methods for treating ocular neovascular diseases. OA12720A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33230401P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
OA12720A true OA12720A (en) 2006-06-27

Family

ID=23297643

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400130A OA12720A (en) 2001-11-09 2002-11-08 Methods for treating ocular neovascular diseases.

Country Status (26)

Country Link
US (3) US20030171320A1 (zh)
EP (1) EP1441743A4 (zh)
JP (1) JP2005511576A (zh)
KR (1) KR20050044372A (zh)
CN (1) CN1582156A (zh)
AP (1) AP1750A (zh)
AR (1) AR037307A1 (zh)
BR (1) BR0213975A (zh)
CA (1) CA2464007A1 (zh)
CR (1) CR7330A (zh)
EA (1) EA006746B1 (zh)
EC (1) ECSP045098A (zh)
GE (1) GEP20063755B (zh)
HR (1) HRP20040406A2 (zh)
IL (1) IL161327A0 (zh)
IS (1) IS7215A (zh)
MA (1) MA27145A1 (zh)
MX (1) MXPA04004363A (zh)
NO (1) NO20041882L (zh)
OA (1) OA12720A (zh)
PL (1) PL371929A1 (zh)
RS (1) RS35404A (zh)
TN (1) TNSN04081A1 (zh)
TW (1) TWI260327B (zh)
WO (1) WO2003039404A2 (zh)
ZA (1) ZA200402753B (zh)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1253943B1 (en) 2000-02-10 2008-09-03 MASSACHUSETTS EYE & EAR INFIRMARY Photodynamic therapy for treating conditions of the eye
US6942655B2 (en) * 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
US20060231107A1 (en) * 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
CA2876822C (en) 2003-08-27 2015-11-17 David Shima Combination therapy for the treatment of ocular neovascular disorders
US7575321B2 (en) * 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20060030535A1 (en) * 2004-03-05 2006-02-09 Healy Judith M Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
ES2450541T3 (es) * 2004-06-04 2014-03-25 The Scripps Research Institute Composiciones para el tratamiento de enfermedades neovasculares
JP2008507284A (ja) * 2004-07-23 2008-03-13 （オーエスアイ）アイテツク・インコーポレーテツド デュアルハイブリダイゼーションによるオリゴヌクレオチドの検出
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
DK1802334T3 (da) * 2004-10-21 2012-10-15 Genentech Inc Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
AU2012200865A1 (en) * 2004-10-21 2012-03-29 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006047716A2 (en) * 2004-10-26 2006-05-04 Bioresponse Llc Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
JP2008533204A (ja) * 2005-03-21 2008-08-21 マクサイト， インコーポレイテッド 病気又は症状の治療のためのドラッグ送達システム
US20060293270A1 (en) * 2005-06-22 2006-12-28 Adamis Anthony P Methods and compositions for treating ocular disorders
JPWO2007037188A1 (ja) * 2005-09-27 2009-04-09 北海道公立大学法人 札幌医科大学 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2622312A1 (en) * 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
US8492400B2 (en) * 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
CN103127100A (zh) 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
WO2007149334A2 (en) * 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
WO2008103320A1 (en) * 2007-02-16 2008-08-28 Novacea, Inc. Methods of treating ophthalmic disorders with anthraquinones
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN101873797A (zh) 2007-10-19 2010-10-27 萨可德公司 用于治疗糖尿病性视网膜病的组合物和方法
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
CA2747219C (en) * 2008-12-16 2017-12-12 Qlt Inc. Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
JP2012517434A (ja) * 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN102711756A (zh) * 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JPWO2012105610A1 (ja) 2011-02-02 2014-07-03 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
KR101303920B1 (ko) * 2011-04-26 2013-09-05 서울대학교산학협력단 프로토포르피린 ＩＸ 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
CN103721257B (zh) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 光敏素催化分解过氧化氢系列药物
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
RU2527360C1 (ru) * 2013-04-23 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ комбинированного лечения ретиноваскулярного макулярного отека
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
US10183989B2 (en) * 2013-12-24 2019-01-22 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108431019A (zh) 2015-10-07 2018-08-21 阿佩利斯制药有限公司 给药方案
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
MX2019012033A (es) 2017-04-07 2019-12-05 Apellis Pharmaceuticals Inc Regímenes de dosificación y composiciones y métodos relacionados.
DE102017008721A1 (de) 2017-09-16 2019-03-21 protectismundi GmbH Verfahren und Vorrichtung zur Hochhausbrandbekämfpung
AU2019227997A1 (en) 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113101530B (zh) * 2021-04-14 2022-09-30 中国人民解放军陆军特色医学中心 一种通过无线充电激活玻璃体腔植入性发光二极管的系统
KR20240121668A (ko) 2023-02-01 2024-08-09 아주대학교산학협력단 염증성 눈질환의 예방 및 치료용 조성물
CN118108804B (zh) * 2024-04-26 2024-06-25 山东大学 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
CA2536069C (en) * 1994-03-14 2008-06-03 Massachusetts Eye And Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
JP3845469B2 (ja) * 1996-02-21 2006-11-15 明治製菓株式会社 眼底の新生血管の閉塞に用いる投与剤
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
ES2259188T3 (es) * 1996-10-25 2006-09-16 Gilead Sciences, Inc. Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf).
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
AU2001227837A1 (en) * 2000-01-12 2001-07-24 Light Sciences Corporation Novel treatment for eye disease
EP1253943B1 (en) * 2000-02-10 2008-09-03 MASSACHUSETTS EYE & EAR INFIRMARY Photodynamic therapy for treating conditions of the eye
JP2003529567A (ja) * 2000-03-10 2003-10-07 インサイト・ビジョン・インコーポレイテッド 後眼部眼疾患を治療および予防する方法と組成物
AR032151A1 (es) * 2000-03-24 2003-10-29 Novartis Ag Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization

Also Published As

Publication number Publication date
EA200400518A1 (ru) 2004-12-30
MXPA04004363A (es) 2005-05-16
CN1582156A (zh) 2005-02-16
AP2004003026A0 (en) 2004-06-30
IS7215A (is) 2004-04-07
HRP20040406A2 (en) 2005-02-28
WO2003039404A3 (en) 2004-02-12
MA27145A1 (fr) 2005-01-03
ECSP045098A (es) 2004-07-23
AP1750A (en) 2007-06-23
ZA200402753B (en) 2005-01-05
US20030171320A1 (en) 2003-09-11
TNSN04081A1 (fr) 2006-06-01
GEP20063755B (en) 2006-02-27
JP2005511576A (ja) 2005-04-28
KR20050044372A (ko) 2005-05-12
BR0213975A (pt) 2005-05-10
NO20041882L (no) 2004-05-07
US20040167091A1 (en) 2004-08-26
WO2003039404A2 (en) 2003-05-15
EP1441743A2 (en) 2004-08-04
AR037307A1 (es) 2004-11-03
IL161327A0 (en) 2004-09-27
EP1441743A4 (en) 2009-02-25
TW200302226A (en) 2003-08-01
US20070027101A1 (en) 2007-02-01
EA006746B1 (ru) 2006-04-28
CR7330A (es) 2005-06-15
CA2464007A1 (en) 2003-05-15
TWI260327B (en) 2006-08-21
PL371929A1 (en) 2005-07-11
RS35404A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
OA12720A (en) Methods for treating ocular neovascular diseases.
AU2002230567B2 (en) Compositions for treatment of ocular neovascularization and neural injury
US20060293270A1 (en) Methods and compositions for treating ocular disorders
Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results
US6984655B1 (en) Photodynamic therapy for selectively closing neovasa in eyeground tissue
US20070027102A1 (en) Methods and compositions for treating macular degeneration
AU2002230567A1 (en) Compositions for treatment of ocular neovascularization and neural injury
PL188888B1 (pl) Zastosowanie związku światłoczułego do wytwarzania leku do poprawy ostrości widzenia
US20060166956A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
WO2006065727A1 (en) Enhanced occlusive effect photodynamic therapy
WO2006119211A2 (en) Methods and compositions for treating ocular disorders
AU2002363336A1 (en) Methods for treating ocular neovascular diseases
DE60215864T2 (de) Behandlung von okularen neovaskularen erkrankungen
RU2376957C1 (ru) Способ лечения субретинальной неоваскулярной мембраны
AU2006201701B2 (en) Methods and compositions for treatment of ocular neovascularization and neural injury
RU2262926C1 (ru) Способ лечения диабетической ангио-ретинопатии
KR20020087834A (ko) 신경보호 및 망막보호 안과용 약물